Published October 20, 2025 | Version v1
Preprint Open

Clinical Study Testing the Product "Menstruation" on the Effect of Prostaglandin Production in Saliva During Menstruation

Authors/Creators

  • 1. Faculty of Physical Education and Sport, Charles University

Contributors

Description

Background:

Primary dysmenorrhoea is one of the most frequent gynecological complaints in women of reproductive age. Its main mechanism involves increased endometrial prostaglandin production (particularly PGE₂ and PGF₂α), leading to uterine contractions, ischemia, and pain. Current treatments rely on NSAIDs or hormonal suppression, but interest in non-pharmacological alternatives is growing.

Objective:

To evaluate the effect of the complex dietary supplement Menstruation (Verra Science s.r.o.) on prostaglandin levels and subjective pain perception during menstruation.

Methods:

A prospective, three-arm, controlled, and partially blinded study was conducted with 36 healthy women aged 18–44 years, randomly assigned to:

(1) Product group – taking Menstruation twice daily,

(2) Placebo group – identically looking capsules with sucrose and

(3) Control group – no intervention.

Salivary prostaglandin (PGE₂) levels were measured by ELISA during three consecutive menstrual cycles. Subjective pain was evaluated using a standardized questionnaire and VAS scale.

Results:

After three cycles, prostaglandin levels were significantly lower in the product group compared to the control (p = 0.0004) and placebo groups (p = 0.0057). A time-dependent decline in prostaglandin concentration was observed across cycles. Although a trend towards reduced pain was noted in the product group, interindividual variability prevented statistical significance (p > 0.05). A weak but significant correlation between prostaglandin levels and pain intensity was found (ρ = 0.27; p = 0.0035).

Conclusion:

The supplement Menstruation demonstrated a measurable biological effect on lowering pro-inflammatory prostaglandin levels during menstruation, suggesting a potential non-pharmacological approach for dysmenorrhoea relief. The effect on perceived pain remains inconclusive and warrants further investigation in larger cohorts and over a longer observation period, as the trend appears to strengthen over time.

Files

Clinical testing of the Verra product.pdf

Files (1.1 MB)

Name Size Download all
md5:35d4d2195e4ed58ac1a06e2861985e85
1.1 MB Preview Download

Additional details

Dates

Created
2025-07-21

References

  • O. P. M. Smith, H. N. Jabbour, H. O. D. Critchley Hum. Reprod. 2007, 22, 1450-1456.
  • R. Itani, L. Soubra, S. Karout, D. Rahme, L. Karout, H. M. J. Khojah Korean J. Fam. Med. 2022, 43, 101-108.
  • B. St-Jacques, W. Y. Ma Exp. Neurol. 2014, 261, 354-366.
  • H. Kehlet, T. S. Jensen, C. J. Woolf Lancet. 2006, 367, 1618-1625.
  • Z. Barcikowska, E. Rajkowska-Labon, M. E. Grzybowska, R. Hansdorfer-Korzon, K. Zorena Int. J. Environ. Res. Public Health. 2020, 17, 1191.
  • J. Marjoribanks, R. O. Ayeleke, C. Farquhar, M. Proctor Cochrane Database Syst Rev. 2015, Cd001751.
  • M. C. P. Rees, A. B. M. Anderson, L. M. Demers, A. C. Turnbull Br. J. Obstet. Gynaecol. 1984, 91, 673-680.
  • T. D. Wager, J. K. Rilling, E. E. Smith, A. Sokolik, K. L. Casey, R. J. Davidson, S. M. Kosslyn, R. M. Rose, J. D. Cohen Science. 2004, 303, 1162-1167.
  • L. Colloca, F. Benedetti Nat. Rev. Neurosci. 2005, 6, 545-552.
  • R. Mitsuhashi, A. Sawai, K. Kiyohara, H. Shiraki, Y. Nakata Int. J. Environ. Res. Public Health. 2023, 20, 569.
  • R. Ruscheweyh, F. Nees, M. Marziniak, S. Evers, H. Flor, S. Knecht Clin. J. Pain. 2011, 27, 578-586.